A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
← catalyst calendarNCT06684314 · readout in 1,835 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
100estimated
Sites
10
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-11 | actual | When the study began enrolling |
| Primary completion | 2031-08-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-08-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia A
Intervention
- Drug: Efanesoctocog alfa — also filed as ALTUVIIIO, BIVV001
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in total scores of the Hemophilia Joint Health Score (HJHS) for all joints
measured At 1, 2, 3, 4 and 5 years
Change from baseline in annualized joint bleeding rate (AjBR) for treated and untreated bleeds
measured At 1, 2, 3, 4 and 5 years
Number of target joint development, resolution and/or recurrence
measured At 1, 2 ,3, 4 and 5 years
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed